PURPOSE: Human herpesvirus 6 (HHV6) is an emerging cause of interstitial pneumonia in immunocompromised hosts. However, the clinical significance of a positive PCR test for HHV6 in respiratory samples from patients with hematological malignancies remains unclear. METHODS: We retrospectively studied the features and outcomes of 29 critically ill hematology patients with acute respiratory failure and lung pulmonary infiltrates visible on a chest radiograph, who tested positive for a qualitative PCR for HHV6 in bronchoalveolar lavage fluid. RESULTS: Of the 29 patients, 18 (62%) were stem cell transplant recipients and 11 (38%) had received chemotherapy. All patients had a fever. Clinical manifestations consistent with extra-pulmonary HHV6 disease were noted in 17 (59%) patients. One or more co-pathogens were found in 25 (86%) patients. The four remaining patients diagnosed with HHV6 pneumonia and subsequently recovered with foscarnet therapy. Antiviral therapy was also given to seven patients with co-infections, of whom two ultimately died. CONCLUSIONS: In most cases, HHV6 recovered from BAL fluid is a co-pathogen whose clinical relevance remains undetermined. However, in some cases, HHV6 is the only pathogen, along with disseminated systemic viral disease, and the patient is likely to benefit from foscarnet therapy.
PURPOSE:Human herpesvirus 6 (HHV6) is an emerging cause of interstitial pneumonia in immunocompromised hosts. However, the clinical significance of a positive PCR test for HHV6 in respiratory samples from patients with hematological malignancies remains unclear. METHODS: We retrospectively studied the features and outcomes of 29 critically ill hematologypatients with acute respiratory failure and lung pulmonary infiltrates visible on a chest radiograph, who tested positive for a qualitative PCR for HHV6 in bronchoalveolar lavage fluid. RESULTS: Of the 29 patients, 18 (62%) were stem cell transplant recipients and 11 (38%) had received chemotherapy. All patients had a fever. Clinical manifestations consistent with extra-pulmonary HHV6 disease were noted in 17 (59%) patients. One or more co-pathogens were found in 25 (86%) patients. The four remaining patients diagnosed with HHV6 pneumonia and subsequently recovered with foscarnet therapy. Antiviral therapy was also given to seven patients with co-infections, of whom two ultimately died. CONCLUSIONS: In most cases, HHV6 recovered from BAL fluid is a co-pathogen whose clinical relevance remains undetermined. However, in some cases, HHV6 is the only pathogen, along with disseminated systemic viral disease, and the patient is likely to benefit from foscarnet therapy.
Authors: Alfred Lennart Bissinger; Hermann Einsele; Klaus Hamprecht; Ulricke Schumacher; Reinhard Kandolf; Juergen Loeffler; Christian Aepinus; Thomas Bock; Gerhard Jahn; Holger Hebart Journal: Diagn Microbiol Infect Dis Date: 2005-08 Impact factor: 2.803
Authors: J Rogers; S Rohal; D R Carrigan; S Kusne; K K Knox; T Gayowski; M M Wagener; J J Fung; N Singh Journal: Transplantation Date: 2000-06-27 Impact factor: 4.939
Authors: A Desachy; S Ranger-Rogez; B François; C Venot; I Traccard; H Gastinne; F Denis; P Vignon Journal: Clin Infect Dis Date: 2001-01-15 Impact factor: 9.079
Authors: R W Cone; R C Hackman; M L Huang; R A Bowden; J D Meyers; M Metcalf; J Zeh; R Ashley; L Corey Journal: N Engl J Med Date: 1993-07-15 Impact factor: 91.245
Authors: S Z Salahuddin; D V Ablashi; P D Markham; S F Josephs; S Sturzenegger; M Kaplan; G Halligan; P Biberfeld; F Wong-Staal; B Kramarsky Journal: Science Date: 1986-10-31 Impact factor: 47.728
Authors: Amanda L Olson; Parastoo B Dahi; Junting Zheng; Sean M Devlin; Marissa Lubin; Anne Marie Gonzales; Sergio A Giralt; Miguel-Angel Perales; Esperanza B Papadopoulos; Doris M Ponce; James W Young; Nancy A Kernan; Andromachi Scaradavou; Richard J O'Reilly; Trudy N Small; Genovefa Papanicolaou; Juliet N Barker Journal: Biol Blood Marrow Transplant Date: 2014-02-16 Impact factor: 5.742
Authors: Susanna K P Lau; Jasper F W Chan; Ivan F N Hung; Vincent C C Cheng; Siddharth Sridhar; Cyril C Y Yip; Kwok-Hung Chan; Patrick C Y Woo Journal: Am J Med Date: 2016-05-20 Impact factor: 4.965